HIV mutation literature information.


  Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure.
 PMID: 18992847       2009       Infection, genetics and evolution
Method: Mutations L10F/I/R/V, K20M/R, L24I, L33F, M36I, F53L, I54V/L/A/M/T/S, L63P, A71V/T, G73C/S/T/A, V77I and N88D/S were considered as minor resistance mutations and were also analyzed separately and together as a group.
Result: Conversely, mutations L10V, K20M, Result: Mutation G73S was more prevalent in subtype Binfected adults.


  Darunavir: a review of its use in the management of HIV infection in adults.
 PMID: 19323590       2009       Drugs
Abstract: In a 24-week analysis of pooled data from the POWER 1 and 2 studies in treatment-experienced patients, 11 protease mutations associated with a reduced response to boosted darunavir were identified (V11I, V32I, L33F, I47V, I50V, I54L/M, G73S, L76V, I84V and L89V).


  Role of atazanavir in the treatment of HIV infection.
 PMID: 19436623       2009       Therapeutics and clinical risk management
Introduction: Mutations more significant to be included in the GIQ model are the following: L10F/I/V, K20M/R, L24I, D30N, V32I, L33F, M36I/L, I47V/A, G48V, I50V, I50L, F53L, I54V/L/A/M/T/S, L63P, A71V/T, G73S, V77I, V82A/F/T, I84V, N88D/S and


  Primary HIV-1 drug resistance and polymorphic patterns among injecting drug users (IDUs) in Chennai, Southern India.
 PMID: 19721100       2009       Journal of the International Association of Physicians in AIDS Care (Chicago, Ill.
Abstract: RESULTS: M41LM (1.8%), K65KN (1.8%), and G73GS (2.7%) were found to be associated with low-level resistance to zidovudine (ZDV), stavudine (d4T), abacavir (ABC), didanosine (ddI), emtricitabine (FTC), tenofovir (TDF), and saquinavir (SQV) in each specimen.


  Combating HIV resistance - focus on darunavir.
 PMID: 19209258       2008       Therapeutics and clinical risk management
Abstract: Darunavir resistance-associated mutations have been defined as V11I, V32I, L33F, I47V, I50V, I54L/M, G73S, L76V, I84V, and L89V.


  Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
 PMID: 17854027       2007       Journal of medical virology
Abstract: A series of correlated mutations including L10I, M46I, I54V, A71V, G73S, and L90M appeared as a common cluster of amino acid substitutions, associated with failure to lopinavir/ritonavir-based treatments.
Abstract: On the other hand, L90M together with L10I, I54V, A71V, G73S, and V82A were selected in protease inhibitor-experienced patients.


  Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.
 PMID: 17646201       2007       The Journal of antimicrobial chemotherapy
Abstract: For minor darunavir resistance mutations, the rates were V11I 3.3%, V32I 3.9%, L33F 11%, I47V 2.1%, I54L 2.3%, G73S 12.8% and L89V 2.4%.


  HIV-1 subtype B protease and reverse transcriptase amino acid covariation.
 PMID: 17500586       2007       PLoS computational biology
Method:
Result: However, M46I was uniquely associated with F53L, G73S/T, V82F/T, I84V, and N88S.
Result: The major mutation L90M preceded the accessory mutation G73S in 31 of 34 persons for whom temporal data were available.


  A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
 PMID: 17227139       2007       PLoS medicine
Method: In addition, the model was also adjusted on use of nelfinavir at baseline and on the number of PI mutations (L10IRVF, K20RM, M36I, A71VT, G73SA, V82AFTS, L90M) found to be associated with the virological response in univariate analyses in this subset of patients.


  Resistance mutational analysis of HIV type 1 subtype C among rural South African drug-naive patients prior to large-scale availability of antiretrovirals.
 PMID: 17209775       2006       AIDS research and human retroviruses
Abstract: Ninety-five percent of patients had no major mutations in the protease gene, although substitutions M46L (2.5%) and G73S (2.5%), which according to the Stanford Genotypic Resistance Interpretation Algorithm are considered major mutations, were detected.



Browser Board

 Co-occurred Entities




   Filtrator